Many pharmaceutical drugs originate from nature due to safety profiles and intrinsic biological activity that has been optimized through trial and time. A shift towards natural products is evident from significant interest and clinical data identifying cannabis and psychedelics as emerging therapeutics. Psilera will leverage its research strengths led by executives from the pharmaceutical and cannabis industries to develop a best-in-class IP portfolio of psychedelic analogues. Lead compounds are formulated and screened with neurological targets to evaluate clinical potential with pipeline candidates in the areas of mood disorders, cognitive diseases, and addiction. Psilera’s mission is to make a significant impact on mental health and improve the human condition.